PHARMANUTRA S.P.A.
Research PHARMANUTRA S.P.A. (761) on Bullrun: valuation model: 0.8% undervalued, market cap EUR 822.51M, P/E 39.0, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker761
- ExchangeF
- CountryItaly
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Valuation signal0.8% undervalued
- Market capEUR 822.51M
- P/E39.0
- Dividend yield1.4%
- Financial periodFY2025
- RevenueEUR 131.69M
- Revenue growth14.0%
- Net incomeEUR 20.00M
Valuation Snapshot
Bullrun's latest valuation model marks PHARMANUTRA S.P.A. as 0.8% undervalued; latest market cap is EUR 822.51M; P/E is 39.0; dividend yield is 1.4%.
About PHARMANUTRA S.P.A.
Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects;
Frequently asked questions
Is PHARMANUTRA S.P.A. overvalued or undervalued?
Bullrun's valuation model currently marks PHARMANUTRA S.P.A. as 0.8% undervalued.
What is PHARMANUTRA S.P.A.'s market cap?
PHARMANUTRA S.P.A.'s market capitalization is EUR 822.51M.
What is PHARMANUTRA S.P.A.'s P/E ratio?
PHARMANUTRA S.P.A.'s price-to-earnings (P/E) ratio is 39.0.
Does PHARMANUTRA S.P.A. pay a dividend?
PHARMANUTRA S.P.A. has a dividend yield of 1.4%.
What does PHARMANUTRA S.P.A. do?
Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally.